Showing 5831-5840 of 7126 results for "".
- PE-Backed Ownership of Dermatology Practices Is On The Risehttps://practicaldermatology.com/news/pe-backed-ownership-of-dermatology-practices-is-on-the-rise/2460104/Private equity firms have increased their financial stakes in dermatology practices throughout the United States, but exactly how this affects care is not fully understood yet. Private equity-backed dermatology management groups acquired 184 dermatology practices from 2012 to 2018, with
- DERM2019 Day 4: Contact Dermatitis, Dermoscopy Bootcamp, and Morehttps://practicaldermatology.com/news/derm2019-day-4-contact-dermatitis-dermoscopy-bootcamp-and-more/2460103/The last day of DERM2019 included a dermoscopy session and several other key presentations from Jennifer Stein, David Cohen, and Gilly Munavalli. Here’s a brief recap from some of those talks! Dermoscopy Bootcamp Presented by Jennifer Stein
- RealSelf Releases 2019 Sun Safety Reporthttps://practicaldermatology.com/news/realself-releases-2019-sun-safety-report/2460102/According to the 2019 RealSelf Sun Safety Report, only 1 in 10 adults in the US uses sunscreen every day, and almost half (47 percent) of Americans never wear sunscreen, and women are significantly more likely than men to wear sunscreen on
- Modernizing Medicine: New Capabilities Address Price Transparency, Patient Engagementhttps://practicaldermatology.com/news/modernizing-medicine-new-capabilities-address-price-transparency-patient-engagement/2460100/Modernizing Medicine® will showcase new and enhanced capabilities for price transparency, digital patient engagement and more to the company’s electronic health records (EHR) platform, EMA®, and Practice Management system at the American Academy of Dermatology (AAD) 2019 S
- Vehicles, Infectious Disease, and Acne Updates from Day 2 at DERM2019https://practicaldermatology.com/news/vehicles-infectious-disease-and-acne-updates-from-day-2-at-derm2019/2460099/The DERM2019 NP/PA CME Conference continued to delight audiences with esteemed faculty presenters, including those who presented Friday, including April Armstrong, David Cohen, Kara Gooding, Joseph Gorelick, Julie Harper, Jayme Heim, George Keough, Leon Kircik, Kristine Kucera, Gilly Munavalli, T
- Baylor Dermatologist Offers Anti-Aging Advice in Response to FaceApp Crazehttps://practicaldermatology.com/news/baylor-dermatologist-offers-anti-aging-advice-in-response-to-faceapp-craze/2460097/The FaceApp is taking social media by storm as celebrities and social media users across the nation morph their faces to look decades older. While it is currently being used for comedic purposes, you may have patients asking how to keep the app from turning into reality. Rajani Katta, M
- Revance Adds New Member to Board of Directorshttps://practicaldermatology.com/news/revance-adds-new-member-to-board-of-directors/2460096/Chris Nolet is the newest member of Revance Therapeutics, Inc.’s Board of Directors. He will serve as the Chair of the Revance Audit Committee. “Chris Nolet brings an extraordinary record of industry-shaping consultation to the Revance Bo
- Novartis Offers Free Genetic Testing for Advanced Melanomahttps://practicaldermatology.com/news/novartis-offers-free-genetic-testing-for-advanced-melanoma/2460095/The Know Now Testing Program is an initiative from Novartis in collaboration with Quest Diagnostics that offers genetic mutation testing at no cost for all patients with stage III or stage IV melanoma. Nearly half of all advanced melanoma patients carry a specific mutation, called BRAF.
- New to SENTE BOD: Clint Carnell and Clement Gingrashttps://practicaldermatology.com/news/new-to-sente-bod-clint-carnell-and-clement-gingras/2460093/SENTÉ has appointed Clint Carnell and Clement Gingras to its Board of Directors effective immediately. "We are thrilled to have both Clint and Clement join the SENTÉ team," says Faheem Hasnain, Chairman of t
- Proof of Concept Study Supports Dermata’s Topical Delivery Mechanism for Botulinum Toxinhttps://practicaldermatology.com/news/proof-of-concept-study-supports-dermatas-topical-delivery-mechanism-for-botulinum-toxin/2460089/Dermata Therapeutics’ DMT410 (DMT310 + botulinum toxin) performed well in a Phase 1proof of concept study for the treatment of primary axillary hyperhidrosis, the Company reports. DMT410 is a combination regimen for the treatment of skin